105 related articles for article (PubMed ID: 8240736)
1. Induction of B cell tumor dormancy by anti-idiotypic antibodies.
Yefenof E; Picker LJ; Scheuermann RH; Vitetta ES; Street NE; Tucker TF; Uhr JW
Curr Opin Immunol; 1993 Oct; 5(5):740-4. PubMed ID: 8240736
[TBL] [Abstract][Full Text] [Related]
2. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.
Racila E; Scheuermann RH; Picker LJ; Yefenof E; Tucker T; Chang W; Marches R; Street NE; Vitetta ES; Uhr JW
J Exp Med; 1995 Apr; 181(4):1539-50. PubMed ID: 7535341
[TBL] [Abstract][Full Text] [Related]
3. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
Davis TA; Maloney DG; Czerwinski DK; Liles TM; Levy R
Blood; 1998 Aug; 92(4):1184-90. PubMed ID: 9694706
[TBL] [Abstract][Full Text] [Related]
5. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.
Rabinovsky R; Uhr JW; Vitetta ES; Yefenof E
Adv Cancer Res; 2007; 97():189-202. PubMed ID: 17419946
[TBL] [Abstract][Full Text] [Related]
6. Dormancy in a model of murine B cell lymphoma.
Uhr JW; Marches R
Semin Cancer Biol; 2001 Aug; 11(4):277-83. PubMed ID: 11513563
[TBL] [Abstract][Full Text] [Related]
7. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established.
Vitetta ES; Tucker TF; Racila E; Huang YW; Marches R; Lane N; Scheuermann RH; Street NE; Watanabe T; Uhr JW
Blood; 1997 Jun; 89(12):4425-36. PubMed ID: 9192767
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants.
George AJ; McBride HM; Glennie MJ; Smith LJ; Stevenson FK
Hybridoma; 1991 Apr; 10(2):219-27. PubMed ID: 1908435
[TBL] [Abstract][Full Text] [Related]
9. Cancer dormancy: studies of the murine BCL1 lymphoma.
Uhr JW; Tucker T; May RD; Siu H; Vitetta ES
Cancer Res; 1991 Sep; 51(18 Suppl):5045s-5053s. PubMed ID: 1884380
[TBL] [Abstract][Full Text] [Related]
10. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
11. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
12. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
13. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.
Moshitzky S; Kukulansky T; Haimovich J; Hollander N
Immunol Cell Biol; 2008; 86(3):261-7. PubMed ID: 18195726
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
16. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of B lymphoma by anti-idiotype antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation.
Taya M; Haimovich J
Cancer Immunol Immunother; 1991; 34(1):43-8. PubMed ID: 1760810
[TBL] [Abstract][Full Text] [Related]
18. Cancer dormancy: isolation and characterization of dormant lymphoma cells.
Yefenof E; Picker LJ; Scheuermann RH; Tucker TF; Vitetta ES; Uhr JW
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1829-33. PubMed ID: 8446596
[TBL] [Abstract][Full Text] [Related]
19. The Role of Regulatory B Cell-Like Malignant Cells and Treg Cells in the Mouse Model of BCL1 Tumor Dormancy.
BitMansour A; Pop LM; Vitetta ES
PLoS One; 2016; 11(12):e0167618. PubMed ID: 27959896
[TBL] [Abstract][Full Text] [Related]
20. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
Int Rev Immunol; 1989; 4(4):251-70. PubMed ID: 2519929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
